Mehrdad Emami

Mehrdad Emami

Auto-generated profile, based on publicly available information

Mehrdad Emami

Centre for Heart Rhythm Disorders, The University of Adelaide , Adelaide

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
ATAnand Thiyagarajah
Anand Thiyagarajah
KKKadhim Kadhim
Kadhim Kadhim
DLDennis H. Lau
Dennis H. Lau
MEMehrdad Emami
Mehrdad Emami
Dominik LinzDominik Linz
Dominik Linz
PSPrashanthan Sanders
Prashanthan Sanders
Background: The posterior left atrium is an arrhythmogenic substrate that contributes to the initiation and maintenance of atrial fibrillation (AF); however, the feasibility, safety, and efficacy of posterior wall isolation (PWI) as an AF ablation strategy has not been widely reported. Methods: We undertook a systematic review and meta-analysis of studies performing PWI to assess (1) acute procedural success including the ability to achieve PWI and the number of procedure-related complications, (2) Long-term, clinical success including rates of arrhythmia recurrence and posterior wall reconnection, and (3) The efficacy of PWI compared with pulmonary vein isolation on preventing arrhythmia recurrence. MEDLINE, EMBASE, and Web of Science databases were searched in May 2018 to retrieve relevant studies. Results were pooled using a random effects model. Results: Seventeen studies (13 box isolation, 3 single ring isolation, and 1 debulking ablation) comprising 1643 patients (31.3% paroxysmal AF, left atrial diameter 41±3.1 mm) were included in the final analysis. In studies focusing specifically on PWI, the acute procedural success rate for achieving PWI was 94.1% (95% CI, 87.2%–99.3%). Single-procedure 12-month freedom from atrial arrhythmia was 65.3% (95% CI, 57.7%–73.9%) overall and 61.9% (54.2%–70.8%) for persistent AF. Randomized control trials comparing PWI to pulmonary vein isolation (3 studies, 444 patients) yielded conflicting results and could not confirm an incremental benefit to PWI. Fifteen major complications (0.1%), including 2 atrio-esophageal fistulas, were reported. Conclusions: PWI as an end point of AF ablation can be achieved in a large proportion of cases with good rates of 12-month freedom from atrial arrhythmia. Although the procedure-related complication rate is low, it did not eliminate the risk of atrio-esophageal fistula. Registration: URL: http://www.crd.york.ac.uk/prospero . PROSPERO registration number: CRD42018107212.

20 March 2024 in JACC: Heart Failure
Verified
Journal Article
Closed access
JAJonathan P. Ariyaratnam
Jonathan P. Ariyaratnam
RMRicardo S. Mishima
Ricardo S. Mishima
KKKadhim Kadhim
Kadhim Kadhim
MEMehrdad Emami
Mehrdad Emami
JFJohn Fitzgerald
John Fitzgerald
AEAdrian D. Elliott
Adrian D. Elliott

2 May 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
PSPrashanthan Sanders
Prashanthan Sanders
SHStewart Healy
Stewart Healy
MEMehrdad Emami
Mehrdad Emami
EKEmily Kotschet
Emily Kotschet
AMAmber Miller
Amber Miller
JKJonathan M Kalman
Jonathan M Kalman
Pulsed field ablation (PFA) for the treatment of atrial fibrillation (AF) potentially offers improved safety and procedural efficiencies compared with thermal ablation. Opportunities remain to improve effective circumferential lesion delivery, safety, and workflow of first-generation PFA systems. In this study, we aim to evaluate the initial clinical experience with a balloon-in-basket, 3D integrated PFA system with a purpose-built form factor for pulmonary vein (PV) isolation. The VOLT CE Mark Study is a pre-market, prospective, multi-centre, single-arm study to evaluate the safety and effectiveness of the Volt™ PFA system for the treatment of paroxysmal (PAF) or persistent AF (PersAF). Feasibility sub-study subjects underwent phrenic nerve evaluation, endoscopy, chest computed tomography, and cerebral magnetic resonance imaging. Study endpoints were the rate of primary serious adverse event within 7 days and acute procedural effectiveness. A total of 32 subjects (age 61.6 ± 9.6 years, 65.6% male, 84.4% PAF) were enrolled and treated in the feasibility sub-study and completed a 30-day follow-up. Acute effectiveness was achieved in 99.2% (127/128) of treated PVs (96.9% of subjects, 31/32) with 23.8 ± 4.2 PFA applications/subject. Procedure, fluoroscopy, LA dwell, and transpired ablation times were 124.6 ± 28.1, 19.8 ± 8.9, 53.0 ± 21.0, and 48.0 ± 19.9 min, respectively. Systematic assessments of initial safety revealed no phrenic nerve injury, pulmonary vein stenosis, or oesophageal lesions causally related to the PFA system and three subjects with silent cerebral lesions (9.4%). There were no primary serious adverse events. The initial clinical use of the Volt PFA System demonstrates acute safety and effectiveness in the treatment of symptomatic, drug refractory AF.

1 December 2018 in Heart Rhythm
Verified
Journal Article
Closed access
DMDian A. Munawar
Dian A. Munawar
RMRajiv Mahajan
Rajiv Mahajan
Dominik LinzDominik Linz
Dominik Linz
GWGeoffrey R. Wong
Geoffrey R. Wong
KKKashif B. Khokhar
Kashif B. Khokhar
DLDennis H Lau
Dennis H Lau

30 January 2020 in EP Europace
Verified
Journal Article
Closed access
DMDian A Munawar
Dian A Munawar
JCJoel Ern Zher Chan
Joel Ern Zher Chan
MEMehrdad Emami
Mehrdad Emami
KKKadhim Kadhim
Kadhim Kadhim
KKKashif Khokhar
Kashif Khokhar
DLDennis H Lau
Dennis H Lau
Aims: There is growing evidence that magnetic resonance imaging (MRI) scanning in patients with non-conditional cardiac implantable electronic devices (CIEDs) can be performed safely. Here, we aim to assess the safety of MRI in patients with non-conditional CIEDs. Methods and results: English scientific literature was searched using PubMed/Embase/CINAHL with keywords of ‘magnetic resonance imaging’, ‘pacemaker’, ‘implantable defibrillator’, and ‘cardiac resynchronization therapy’. Studies assessing outcomes of adverse events or significant changes in CIED parameters after MRI scanning in patients with non-conditional CIEDs were included. References were excluded if the MRI conditionality of the CIEDs was undisclosed; number of patients enrolled was 0.5 V and impedance >50Ω was seen in 1.1% [95% confidence interval (CI) 0.7–1.8%] and 4.8% (95% CI 3.3–6.4%) respectively. The incidence of reduction in P- and R-wave sensing by >50% was 1.5% (95% CI 0.6–2.9%) and 0.4% (95% CI 0.06–1.1%), respectively. Battery voltage reduction of >0.04 V was reported in 2.2% (95% CI 0.2–6.1%). Conclusion: This meta-analysis affirms the safety of MR imaging in non-conditional CIEDs with no death or implantable cardioverter-defibrillator shocks and extremely low incidence of lead or device-related complications.

1 November 2021 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
COCatherine J. O’sHea
Catherine J. O’sHea
MMMelissa E. Middeldorp
Melissa E. Middeldorp
JHJeroen M.H Hendriks
Jeroen M.H Hendriks
ABAnthony G. Brooks
Anthony G. Brooks
CHCurtis Harper
Curtis Harper
PSPrashanthan Sanders
Prashanthan Sanders